Tumor-suppressing multi-enterobacteria and PD-1/PD-L1 immune checkpoint inhibitor combination improves the outcome of hepatocellular carcinoma therapy

ObjectiveProgrammed death 1 (PD-1) and its ligand PD-L1 inhibitors and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibodies have been approved for the treatment of advanced hepatocellular carcinoma (HCC), but the response rates of these immunotherapy are not high, and they are...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Dongjuan Wu, Yaohua Fan, Mingsheng Zhang, Xiaoguang Wang, Xuesong He, Xinwei Guo, Yangchen Liu, Chenxi Cao, Zhaoqun Deng
Format:	Artigo
Język:	Inglês
Wydane:	Frontiers Media S.A. 2025-06-01
Seria:	Frontiers in Immunology
Hasła przedmiotowe:	tumor-suppressing multi-enterobacteria hepatocellular carcinoma intestinal microbiota tumor immune microenvironment anti-programmed death-1 monoclonal antibody anti-programmed death ligand-1 (PD-L1) monoclonal antibody
Dostęp online:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1598436/full
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!